Evidence map›Paper›PMID 38417967›Full record

ArticleBMJ open2024

Impact of the pandemic and concomitant COVID-19 on the management and outcomes of middle cerebral artery strokes: a nationwide registry-based study.

Abdul Karim Ghaith, Victor Gabriel El-Hajj, Elias Atallah, Jorge Rios Zermeno, Krishnan Ravindran, Maria Gharios, Harry Hoang, Mohamad Bydon, Marcus Ohlsson, Adrian Elmi-Terander and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Abdul Karim Ghaith *Mayo Clinic, Rochester, Minnesota, USA.
Victor Gabriel El-Hajj *Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0001-9479-761X
Elias AtallahNeurological Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Jorge Rios ZermenoMayo Clinic in Florida, Jacksonville, Florida, USA.ORCID 0000-0002-5239-7041
Krishnan RavindranMayo Clinic in Florida, Jacksonville, Florida, USA.
Maria GhariosClinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Harry HoangMayo Clinic, Rochester, Minnesota, USA.
Mohamad BydonMayo Clinic, Rochester, Minnesota, USA.
Marcus OhlssonClinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Adrian Elmi-TeranderClinical Neuroscience, Karolinska Institute, Stockholm, Sweden adrian.elmi.terander@ki.se.ORCID 0000-0002-3776-6136
Rabih G TawkMayo Clinic in Florida, Jacksonville, Florida, USA.
Pascal JabbourNeurosurgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Karolinska Institutet · SEJacksonville College · USMayo Clinic · USThomas Jefferson University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the impact of the COVID-19 pandemic as well as concomitant COVID-19 itself on stroke care, focusing on middle cerebral artery (MCA) territory infarctions.

designRegistry-based study.

settingWe used the National Inpatient Sample (NIS) database, which covers a wide range of hospitals within the USA.

participantsThe NIS was queried for patients with MCA strokes between 2016 and 2020. In total, 35 231 patients were included. OUTCOME MEASURES: Outcome measures were postprocedural complications, length of stays (LOSs), in-hospital mortality and non-routine discharge. Propensity score matching using all available baseline variables was performed to reduce confounders when comparing patients with and without concomitant COVID-19.

resultsMechanical thrombectomy (MT) was performed in 48.4%, intravenous thrombolysis (IVT) in 38.2%, and both MT and IVT (MT+IVT) in 13.4% of patients. A gradual increase in the use of MT and an opposite decrease in the use of IVT (p<0.001) was detected during the study period. Overall, 25.0% of all patients were admitted for MCA strokes during the pandemic period (2020), of these 209 (2.4%) were concomitantly diagnosed with COVID-19. Patients with MCA strokes and concomitant COVID-19 were significantly younger (64.9 vs 70.0; p<0.001), had significantly worse NIH Stroke Severity scores, and worse outcomes in terms of LOS (12.3 vs 8.2; p<0.001), in-hospital mortality (26.3% vs 9.8%; p<0.001) and non-routine discharge (84.2% vs 76.9%; p=0.013), as compared with those without COVID-19. After matching, only in-hospital mortality rates remained significantly higher in patients with COVID-19 (26.7% vs 8.5%; p<0.001). Additionally, patients with COVID-19 had higher rates of thromboembolic (12.3% vs 7.6%; p=0.035) and respiratory (11.3% vs 6.6%; p=0.029) complications.

conclusionsAmong patients with MCA stroke, those with concomitant COVID-19 were significantly younger and had higher stroke severity scores. They were more likely to experience thromboembolic and respiratory complications and in-hospital mortality compared with matched controls.

Indexed as

Brain IschemiaCOVID-19StrokeFibrinolytic AgentsHumansInfarction, Middle Cerebral ArteryPandemicsRegistriesThrombectomyThrombolytic TherapyTreatment OutcomeFibrinolytic AgentsCOVID-19neurologystroke

Identifiers

PMID38417967
PMCPMC10900352
OpenAlexW4392244790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.